| Literature DB >> 33869237 |
Yaowang Lin1, Shaohong Dong1, Jie Yuan1, Danqing Yu2, Weijie Bei1, Ruimian Chen1, Haiyan Qin3.
Abstract
This study aimed to evaluate the accuracy and prognostic value of the sequential organ failure assessment (SOFA) score combined with C-reactive protein (CRP) in patients with complicated infective endocarditis (IE). A total of 246 consecutive patients with complicated IE were included in the multicentric prospective observational study. These patients were divided into four groups depending on the SOFA score and CRP optimal cutoff values (≥5 points and ≥17.6 mg/L, respectively), which were determined using the receiver operating characteristic analysis: low SOFA and low CRP (n = 83), low SOFA and high CRP (n = 87), high SOFA and low CRP (n = 25), and high SOFA and high CRP (n = 51). The primary endpoint was in-hospital death, and the secondary endpoint was long-time mortality, defined as subsequent readmission and 3-years mortality in the follow-up period. High SOFA score and high CRP were associated with approximately 29.410% (15/51) of higher incidence of in-hospital death with an area under the curve of 0.872. Multivariate analyses showed that age [odds ratio (OR) = 2.242, 1.142-4.401], neurological failure (Glasgow Coma Scale ≤ 12) (OR = 2.513, 1.041-4.224), Staphylococcus aureus (OR = 2.151, 1.252-4.513), SOFA ≥ 5 (OR = 9.320, 3.621-16.847), and surgical treatment (OR = 0.121, 0.031-0.342) were clinical predictors for in-hospital death. On following up for 12-36 months, SOFA ≥ 5 (p = 0.000) showed higher mortality. A high SOFA score combined with increased CRP levels is associated with in-hospital mortality. Also, SOFA score, but not CRP, predicts long-term mortality in complicated IE.Entities:
Keywords: C-reactive protein; SOFA; complicated infective endocarditis; in-hospital death; long-time outcome 3
Year: 2021 PMID: 33869237 PMCID: PMC8044865 DOI: 10.3389/fmed.2021.576970
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Flowchart of the statistical analysis. *Patients were excluded on having non-complicated infective endocarditis (n = 90), prior infective endocarditis (n = 10), age <18 years (n = 12), and others (n = 4).
Baseline clinical characteristics of patients according to SOFA and CRP.
| Age (year) | 41.86 ± 12.82 | 43.34 ± 13.93 | 47.88 ± 13.89 | 46.24 ± 13.52 | 0.126 |
| Males, | 64 (77.11) | 56 (64.37) | 18 (72.00) | 40 (78.43) | 0.781 |
| AIE, | 11 (13.25) | 19 (21.84) | 4 (16.00) | 10 (19.61) | 0.442 |
| SIE, | 72 (86.75) | 68 (78.16) | 21 (84.00) | 41 (80.39) | 0.512 |
| Hypertension, | 6 (7.22) | 8 (9.20) | 3 (12.0) | 9 (17.65) | 0.054 |
| Diabetes mellitus, | 0 (0) | 3 (3.45) | 0 (0) | 5 (9.80) | |
| Affected valve | |||||
| Aortic valve, | 35 (42.17) | 37 (42.53) | 11 (44.0) | 28 (54.90) | 0.149 |
| Mitral valve, | 41 (49.40) | 50 (57.47) | 11 (44.0) | 24 (47.06) | 0.603 |
| Triple vale, | 7 (8.43) | 13 (14.94) | 3 (12.0) | 6 (11.76) | 0.612 |
| Multiple valves, | 8 (9.64) | 9 (10.34) | 2 (8.0) | 4 (7.84) | 0.745 |
| Congenital heart disease, | 14 (16.87) | 8 (9.20) | 3 (12.0) | 6 (11.76) | 0.416 |
| Neurological failure (GCS ≤ 12), | 6 (7.22) | 7 (8.05) | 2 (8.0) | 3 (5.88) | 0.788 |
| Paravalvular abscess, | 4 (4.82) | 10 (11.49) | 1 (4.0) | 4 (7.84) | 0.707 |
| Stroke, | 1 (1.20) | 7 (8.05) | 4 (16.0) | 14 (27.45) | |
| Heart failure, | 41 (49.40) | 43 (49.43) | 12 (48.0) | 31 (60.78) | 0.238 |
| NYHA III–IV, | 35 (42.17) | 38 (43.68) | 8 (32.00) | 28 (54.90) | 0.273 |
| LVEF (%) | 63.50 ± 8.74 | 62.58 ± 9.78 | 67.12 ± 8.67 | 60.64 ± 9.38 | |
| Temperature, °C | 38.8 ± 1.17 | 38.75 ± 0.57 | 38.95 ± 0.76 | 39.08 ± 0.72 | 0.922 |
| Pathogen, n (%) | |||||
| 2 (2.41) | 8 (9.20) | 3 (12.0) | 14 (27.45) | ||
| 10 (12.05) | 11 (12.64) | 4 (16.0) | 9 (17.65) | 0.052 | |
| Healthcare-associated infection | 2 (2.47) | 2 (2.31) | 1 (4.0) | 3 (5.88) | 0.425 |
| WBC, × 109/L | 7.3 ± 2.6 | 9.4 ± 3.7 | 8.4 ± 3.7 | 11.4 ± 2.7 | |
| CRP, mg/L | 7.10 ± 5.23 | 39.89 ± 27.29 | 8.98 ± 6.88 | 37.95 ± 17.18 | 0.000 |
| SOFA score | 3.08 (3, 4) | 3.21 (3, 4) | 5.68 (5, 7) | 6.51 (5, 8) | 0.000 |
| ESR, mm/h | 20.22 ± 20.51 | 54.30 ± 36.61 | 28.32 ± 27.45 | 36.67 ± 31.88 | 0.000 |
| Vegetation size ≥10 mm, | 24 (29.63) | 41 (47.13) | 11 (44.0) | 29 (56.86) | |
| Surgery treatment, | 77 (95.06) | 77 (88.51) | 22 (88.0) | 35 (68.63) | |
| In-hospital deaths | 2 (2.47) | 1 (1.15) | 3 (12.0) | 15 (29.41) | |
| Longtime mortality | 0 (0) | 6 (6.90) | 2 (8.0) | 8 (15.69) |
AIE, acute infective endocarditis; SIE, subacute infective endocarditis; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; WBC, white blood cell; CRP:C-reactive protein; ESR, erythrocyte sedimentation rate; SOFA, sequential organ failure assessment; GCS, Glasgow coma score. Italic values defined as reference value.
Figure 2ROC curves for SOFA and CRP in predicting in-hospital death.
Univariate and multivariate analyses of factors associated with in-hospital mortality.
| 43.23 ± 13.19 | 54.77 ± 14.10 | 2.18 | 2.242 (1.142–4.401) | |||
| Males, | 164 (72.89) | 14 (66.67) | 1.34 | 0.543 | ||
| AIE, | 40 (17.78) | 4 (19.05) | – | – | ||
| SIE, | 185 (82.22) | 17 (80.95) | 0.92 | 0.884 | ||
| Hypertension, | 21 (9.33) | 5 (23.81) | 3.05 | |||
| Diabetes mellitus, | 6 (2.67) | 2 (9.52) | 3.84 | 0.114 | ||
| Affected valve | ||||||
| Aortic valve, | 97 (43.11) | 13 (61.90) | 2.07 | 0.120 | ||
| Mitral valve, | 117 (52.0) | 9 (42.86) | 0.91 | 0.831 | ||
| Triple vale, | 28 (12.44) | 1 (4.76) | 0.34 | 0.308 | ||
| Multiple valves, | 20 (8.89) | 2 (9.52) | 1.01 | 0.761 | ||
| Congenital heart disease, | 28 (12.44) | 3 (14.29) | 1.16 | 0.820 | ||
| Neurological failure (GCS ≤ 12), | 14 (6.22) | 4 (19.05) | 3.55 | 2.513 | ||
| Paravalvular abscess, | 17 (7.56) | 2 (9.52) | 1.28 | 0.752 | ||
| Stroke, | 20 (8.89) | 6 (28.57) | 4.08 | |||
| Heart failure, | 105 (46.67) | 16 (76.19) | 3.29 | |||
| NYHA III–IV, | 96 (42.) | 13 (61.90) | 2.18 | 0.100 | ||
| #LVEF (%) | 63.10 ± 9.21 | 60.33 ± 24 | 0.39 | 0.78 | ||
| WBC | 7.3 ± 3.1 | 8.8 ± 2.7 | 1.18 | 0.702 | ||
| 23 (10.22) | 4 (19.05) | 2.45 | 2.151 | |||
| 31 (13.78) | 3 (14.29) | 1.05 | 0.841 | |||
| CRP <17.6 mg/L, | 109 (48.66) | 5 (23.81) | – | – | ||
| CRP≥17.6 mg/L, | 116 (51.56) | 16 (76.19) | 3.00 | |||
| 35.96 ± 27.41 | 38.38 ± 23.73 | 1.69 | 0.309 | |||
| Vegetation size ≥10 mm, | 92 (40.89) | 13 | 2.31 | 0.074 | ||
| Surgery treatment, | 200 (89.29) | 10 (47.62) | 0.11 | 0.121 | ||
| Emergency, | 30 (13.39) | 1 (4.76) | – | – | ||
| Urgent, | 39 (17.41) | 1 (4.76) | – | – | ||
| Select, | 131 (58.48) | 6 (28.57) | – | – | ||
| SOFA at admission, | ||||||
| SOFA 0–4 points | 166 (73.78) | 3 (14.29) | – | – | ||
| SOFA ≥5 points | 59 (1.78) | 18 (14.29) | 14.88 | 9.320 |
Age cutoff was 56 years. #LVEF cutoff was 58%. *#ESR cutoff was 56 mm. AIE, acute infective endocarditis; SIE, subacute infective endocarditis; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SOFA, sequential organ failure assessment; GCS, Glasgow coma score. Italic values defined as reference value.
Figure 3Kaplan–Meier curves of SOFA scores (A) and CRP levels (B) for survival over 3 years of follow-up.